Journal of Clinical & Experimental Pharmacology

Franciska Erdo

Biography

Dr. Erdo received her PhD degree at Semmelweis University of Medicine in Budapest in 1997. Currently she is working as a senior research scientist at the Faculty of Information Technology and Bionics of Pázmány Péter Catholic University in Budapest. Besides the research activity she has also lectures at the University on the subjects of Drug Research and Development and Quality Assurance. During her scientific career she has been involved in many fields of preclinical drug research (experimental stroke models in rodents, small animal surgery, behavioral studies, stem cell implantation, inflammatory and analgesia models etc) for testing lipidperoxydation inhibitors, AMPA receptor antagonists, sodium-channel blockers, HSP70 modulators etc. Her current research is focusing on drug-drug and drug-membrane transporter interactions at the blood- brain barrier. The main techniques applied in her laboratory are in vivo BBB models (using in vivo cerebral microdialysis) for pharmacokinetic-pharmacodynamic studies and also for biomarker investigations in physiological and pathological conditions. She has worked in Germany as a scholarship holder for four years (Max-Planck Institute for Neurological Research, Cologne and Charité University of Medicine, Berlin) and she has experience from the pharmaceutical industry (Sanofi, Budapest) and from research institutes as well (IVAX Drug Research Institute, Budapest). She is the author of several scientific publications in international journals and the editor of a review book on recent advances and new strategies in stroke research. She is the member of Society for Neuroscience, Hungarian Neuroscience Society, Hungarian Stroke Society, FENS, IBRO. She has received several awards as jung pharmacologist at Institute for Drug Research and the first price of Hungarian Pharmacological Society on the research of screening possibilities of interleukin-1 beta release inhibitors.

Research Interest

Neuroscience,Drug Research,Screening possibilities of interleukin-1 beta release inhibitors.